Evidence map›Paper›PMID 34366640›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2021

Non-acidic bifunctional benzothiazole-based thiazolidinones with antimicrobial and aldose reductase inhibitory activity as a promising therapeutic strategy for sepsis.

Antonios Kousaxidis, Lucia Kovacikova, Ioannis Nicolaou, Milan Stefek, Athina Geronikaki

Open access · greenAbstract read
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 27 citations in OpenAlex.

  1. An Investigation of 5-HalogenatedMedicines (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Antonios KousaxidisSchool of Health, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124 Greece.
Lucia KovacikovaInstitute of Experimental Pharmacology and Toxicology, CEM, SAS, Dúbravská cesta 9, 84104 Bratislava, Slovakia.
Ioannis NicolaouSchool of Health, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124 Greece.
Milan StefekInstitute of Experimental Pharmacology and Toxicology, CEM, SAS, Dúbravská cesta 9, 84104 Bratislava, Slovakia.
Athina GeronikakiSchool of Health, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124 Greece.
Aristotle University of Thessaloniki · GRInstitute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life-threatening disease that affects millions of people worldwide. Microbial infections that lead to sepsis syndrome are associated with an increased production of inflammatory molecules. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Herein, a series of previously synthesized benzothiazole-based thiazolidinones that exhibited strong antibacterial and antifungal activities has been evaluated for inhibition efficacy against aldose reductase and selectivity toward aldehyde reductase under in vitro conditions. The most promising inhibitor 5 was characterized with IC

Indexed as

Aldose reductaseAntimicrobialDrug-likenessMolecular dockingSelectivitySepsis

Identifiers

PMID34366640
PMCPMC8335715
OpenAlexW3191098620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.